DEPRESSION-INDUCED ABSENTEEISM IN RELATION TO ANTIHYPERLIPIDEMIC TREATMENT - A STUDY USING GAZEL COHORT DATA

被引：22

作者：

BOUMENDIL, E

TUBERTBITTER, P

机构：

[1] Institut National de la Santé et de la Recherche Médicale (INSERM), U88, Saint Maurice

[2] INSERM U169, Villejuif

来源：

EPIDEMIOLOGY | 1995年 / 6卷 / 03期

关键词：

ANTIHYPERLIPIDEMIC AGENTS; DIET THERAPY; ABSENTEEISM; DEPRESSION; GENDER; PHARMACOEPIDEMIOLOGY; OCCUPATION;

D O I：

10.1097/00001648-199505000-00023

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

We examined the relation between overall 1-year exposure to diet and drugs prescribed for hyperlipidemia and the occurrence of medically certified absence from work with depression during the year of exposure (N = 289). The 17,244 persons studied are middle-aged employees of a national company who volunteered as cohort participants. Depression was more prevalent among those exposed to an antihyperlipidemic diet (N = 1,614) than among those unexposed. After stratification by sex and professional status, we found a prevalence ratio (PR) of 1.83 [95% confidence interval (CI) = 1.30-2.58]. Exposure to simvastatin (N = 376) produced comparable results, with a prevalence ratio of 2.18 (95% CI = 1.18-4.03). For subjects who were not cases in the year of exposure assessment, the hypolipidemic treatments are not associated with depression-induced absenteeism the following year. Our results point to a possible role of prescribed diet and simvastatin in depression-related absenteeism.

引用

页码：322 / 325

页数：4

共 19 条

[1] Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Maenpaa H., Malkonen M., Anttari M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjoblom T., Nikkila E., Helsinki Heart Studv: Pnmarv-prevention trial with gemfibrozil in middle-aged men with dvslipidemia: Safety of treatment, changes in risk factors, and incidence or coronan heart disease, N Engl J Med, 317, pp. 1237-1245, (1987)
[2] Lipid Research Clinics Coronan Priman Prevention Trial results. 1. Reduction in incidence of coronan heart disease, JAMA, 251, pp. 351-364, (1984)
[3] Muldoon M.F., Manuck S.B., Matthews K.A., Lowering cholesterol concentra-tions and mortality: A quantitative review of primary prevention trials, Br Med J, 301, pp. 309-314, (1990)
[4] Muldoon M.F., Rossouw D.E., Manuck S.B., Glueck C.J., Kaplan D.R., Kaufmann P.G., Low or lowered cholesterol and risk ot death from suicide and trauma, Metabolism, 42, pp. 45-56, (1993)
[5] Dealberto M.J., Ducimettere P., Maiwaro F., Alperovitch A., Serum lipids and depression, Lancet, 341, (1993)
[6] Lechleitner M., Hoppichler F., Konwahnka G., Patsch J.R., Braunsteiner H., Depressive symptoms in hypercholesterolaemic patients treated with pravastatin, Lancet, 340, (1992)
[7] Simvastatin, Lancet, 339, (1992)
[8] Duits N., Bos F.M., Depressive symptoms and cholesterol-lowering drugs, Lancet, 341, (1993)
[9] Brett A.S., Psychologic effects of the diagnosis and treatment of hypercholesterolemia: Lessons from case studies, Am J Med, 91, pp. 642-647, (1991)
[10] Boumendil E.F., Descriptive studv of lipid-modulating drug use in a French protessional population, J Clin Epidemiol, 47, pp. 1163-1171, (1994)

← 1 2 →